Research
Hormonal
The protective effect of semaglutide on limb events was consistent across patient subgroups, including those with diabetes and obesity.
Semaglutide can be considered for diverse populations at risk of PAD.
StrongSupportsmedium confidence
Benefits were consistent across patient subgroups, in patients with diabetes (OR 0.70; 95% CI: 0.57–0.87; P = 0.001) or obesity (OR 0.71; 95% CI: 0.56–0.89; P = 0.003).
Why this rating
Based on a meta-analysis of 19 randomized controlled trials.
Source
Impact of semaglutide on limb events: a meta-analysis of randomized controlled trials
Arturo Cesaro et al. · European Journal of Preventive Cardiology · 2026
Meta-analysisCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →